Clinical trial
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic…
NCT00401570 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00401570 |
|---|---|
| Title | A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer |
| Official title | Phase 2 Open-Label Study of Volociximab (M200) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Not Previously Treated With Chemotherapy |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Volociximab, Gemcitabine |
| Enrollment | 40 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 20, 2006 |
| Last update posted | Jan 30, 2013 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: